Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
NCT02075008 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2017-08-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was prematurely terminated after core study CQGE031B2201 failed to meet the primary objective of demonstrating superiority for QGE031 versus placebo.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-08-08Results posted on the registry: Novartis Pharmaceuticals, omalizumab + omalizumab (NCT02161562)
- 2018-07-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580356)
- 2018-07-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580369)
- 2018-07-09Results posted on the registry: University of Virginia, omalizumab + Rhinovirus (strain 16) (NCT02388997)
- 2018-05-01Also stopped (withdrawn): Selina Gierer, D.O., Omalizumab (NCT02742805)
- 2018-03-27Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03478930)
- 2018-03-26Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT02392624)
- 2018-02-19Results posted on the registry: Children's Hospital of The King's Daughters, ANTI-IGE THERAPY (XOLAIR) (NCT00283504)
- 2018-01-31Results posted on the registry: GlaxoSmithKline, Mepolizumab 100mg SC + Albuterol/salbutamol MDIs (NCT02654145)
- 2017-12-18Results posted on the registry: Kari Christine Nadeau, Omalizumab + Food Flour Buildup (NCT02626611)
- 2017-12-12Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03369704)
- 2017-12-11Results posted on the registry: Hoffmann-La Roche, Omalizumab (NCT01922037)
- 2017-12-11Results posted on the registry: Johns Hopkins University, Omalizumab (NCT02023151)
- 2017-11-01Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03328897)
- 2017-10-25Results posted on the registry: Stanford University, Xolair + Placebo (NCT02643862)
- 2017-09-26Results posted on the registry: University of North Carolina, Chapel Hill, Peanut Oral Immunotherapy + Omalizumab (NCT00932282)
- 2017-09-12Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280550)
- 2017-09-12Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280537)
- 2017-08-28Results posted on the registry: Johns Hopkins University, omalizumab (NCT00162773)
- 2017-08-28Also stopped (terminated): Johns Hopkins University, omalizumab (NCT00162773)
- 2017-08-11Also stopped (terminated): Novartis Pharmaceuticals, QGE031 + Placebo (NCT02336425)
- 2017-07-12Results posted on the registry: Johns Hopkins University, omalizumab (NCT00949078)
- 2017-05-19Results posted on the registry: Massachusetts General Hospital, Xolair placebo + Xolair (omalizumab) (NCT01066104)
- 2017-05-03Results posted on the registry: Boston Children's Hospital, Omalizumab + placebo (NCT01781637)
- 2017-04-07Results posted on the registry: Novartis Pharmaceuticals, QGE031 + Placebo (NCT02336425)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision